Cancer Dormancy and Residual Disease
June 19-22, 2018
Hyatt Regency Montreal
Montreal, QC, Canada
View meeting website.
Julio A. Aguirre-Ghiso, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York
Ann F. Chambers, London Regional Cancer Program, London, Ontario, Canada
Cyrus M. Ghajar, Fred Hutchinson Cancer Research Center, Seattle, Washington
Christoph A. Klein, Uni?versity of Regensburg, Regensburg, Germany
Dorothy A. Sipkins, Duke University Medical Center, Durham, North Carolina
Depending on cancer type, between 20-90% of cancer patients present to the clinics
without evidence of manifest metastasis; however, abundant literature indicates that these patients carry minimal residual disease (MRD) and are at considerable risk for relapse and metastasis after initial surgery. Molecular-genetic, cell biological, as well as clinical data generated in the past years have revealed that early systemic cancer and manifest metastasis comprise completely different biological disease states.
This meeting aims to address this emerging biology in cancer research to increase awareness and research efforts and further strengthen the knowledge of MRD biology. This conference will provide a forum to inspire new strategies to treat dormant disease, new imaging and diagnostic tools to track MRD and determine its state (active vs. dormant vs. cured), and new paradigms to make metastasis prevention by targeting dormant disease a reality in the clinic.
||Tuesday, June 19, 2018
||Friday, June 22, 2018
||Hyatt Regency Montreal